Effect of Sofosbuvir plus Ribavirin therapy on hepatitis C patients in Pakistan: a retrospective study

Effect of Sofosbuvir plus Ribavirin therapy on hepatitis C patients in Pakistan: a retrospective study

Background The annual global deaths from viral hepatitis is 1.4 million. Pakistan has the second highest burden of hepatitis C in the world. There is dire need to evaluate the response of new direct acting antivirals for the treatment of hepatitis C patients in Pakistan. World Health Organization ha...

Full description

Bibliographic Details
Main Authors:	Zubia Jamil, Yasir Waheed, Maryam Malik, Asghar A. Durrani
Format:	Article
Language:	English
Published:	PeerJ Inc. 2018-05-01
Series:	PeerJ
Subjects:	Hepatitis C virus Early Virological Response (EVR) Sofosbuvir Ribavirin End Treatment Response (ETR)
Online Access:	https://peerj.com/articles/4853.pdf

Similar Items

Efficacy and Safety of Sofosbuvir/Velpatasvir Plus Ribavirin in Patients with Hepatitis C Virus-Related Decompensated Cirrhosis
by: Steven Flamm, et al.
Published: (2023-09-01)

Treatment Response to Sofosbuvir and Ribavirin in Chronic Hepatitis C Patients and Comparison of Naive and Treatment Experienced Patients
by: Muhammad Ikhlaq, et al.
Published: (2018-12-01)

The impact of ribavirin on real-world adherence rates in hepatitis C patients treated with sofosbuvir plus simeprevir
by: Walker DR, et al.
Published: (2015-12-01)

Efficacy and safety of sofosbuvir plus ribavirin for Korean patients with hepatitis C virus genotype 2 infection: A retrospective multi-institutional study
by: Young Min Kim, et al.
Published: (2018-09-01)

Does the old-fashioned sofosbuvir plus ribavirin treatment in genotype 2 chronic hepatitis C patients still works for Koreans?
by: Jong Eun Yeon
Published: (2018-09-01)

The predictors of sustained virological response with sofosbuvir and ribavirin in patients with chronic hepatitis C genotype 2
by: Sung Yong Han, et al.
Published: (2021-05-01)

Efficacy and Safety of Generic Sofosbuvir Plus Daclatasvir and Sofosbuvir/Velpatasvir in HCV Genotype 3-Infected Patients: Real-World Outcomes From Pakistan
by: Saima Mushtaq, et al.
Published: (2020-09-01)

Sofosbuvir/velpatasvir plus ribavirin for Child-Pugh B and Child-Pugh C hepatitis C virus-related cirrhosis
by: Chen-Hua Liu, et al.
Published: (2021-10-01)

Treatment of Real-World HCV Genotype 2-Infected Japanese Patients with Sofosbuvir plus Ribavirin
by: Tatsuo Kanda, et al.
Published: (2017-05-01)

Treatment efficacy and tolerability of Sofosbuvir and Ribavirin for chronic hepatitis C infection in post renal transplant patients – A retrospective single centre study
by: B Kirushnan, et al.
Published: (2016-01-01)

Outcomes and predictors of treatment response with sofosbuvir plus daclatasvir with or without ribavirin in Egyptian patients with genotype 4 hepatitis C virus infection
by: Ahmed OA, et al.
Published: (2018-03-01)

Treatment of viral hepatitis C genotypes 1 and 2 by sofosbuvir and ledipasvir with or without ribavirin combination: A possible alternative to pangenotypic treatment in a low-income country?
by: Chantelli Iamblaudiot Razafindrazoto, et al.
Published: (2021-06-01)

Efficacy and Safety of Ledipasvir/Sofosbuvir with and without Ribavirin in Patients with Chronic Hepatitis C Virus Genotype 1 Infection: a meta-analysis
by: Tingting Tao, et al.
Published: (2017-02-01)

Real-life results of sofosbuvir based therapy for patients with hepatitis C
by: D. G. Zhivitsa, et al.
Published: (2019-09-01)

Sofosbuvir/velpatasvir is an effective treatment for patients with hepatitis C and advanced fibrosis or cirrhosis in a real-world setting in Taiwan
by: Yu-Ting Huang, et al.
Published: (2021-06-01)

Effectiveness of Combination Therapy of Sofosbuvir and Daclatasvir in Hepatitis C Positive Hemodialysis Patients Presenting to a Tertiary Care Hospital
by: Qurat Ul Ain, et al.
Published: (2023-10-01)

Effect of IL-28 B Polymorphisms on Early Virological Response (EVR) in Chronic Hepatitis C Patients Treated with Interferon and Ribavirin
by: Madeeha Nazar
Published: (2016-09-01)

Real-life experience of ledipasvir and sofosbuvir for HCV infected Korean patients: a multicenter cohort study
by: Soon Kyu Lee, et al.
Published: (2022-11-01)

The deleterious effects of sofosbuvir and ribavirin (antiviral drugs against hepatitis C virus) on different body systems in male albino rats regarding reproductive, hematological, biochemical, hepatic, and renal profiles and histopathological changes
by: Rana A. Ali, et al.
Published: (2024-03-01)

Effectiveness and Safety of Sofosbuvir-Velpatasvir in Patients with Cirrhosis Associated with Genotype 3 Hepatitis C Infection in Xinjiang, China
by: Abulitifu Y, et al.
Published: (2022-11-01)

Sofosbuvir-Based Therapies Achieved Satisfactory Virological Response in Chinese Individuals with Genotypes 3 and 6 Infections: A Real-World Experience
by: Tang Q, et al.
Published: (2021-06-01)

Full-dose sofosbuvir plus low-dose ribavirin for hepatitis C virus genotype 2-infected patients on hemodialysis
by: Hee Yeon Seo, et al.
Published: (2020-05-01)

Antinuclear antibody titer and treatment response to peginterferon plus ribavirin for chronic hepatitis C patients
by: Ming-Yen Hsieh, et al.
Published: (2012-02-01)

Real-Life Experience with Ledipasvir/Sofosbuvir for the Treatment of Chronic Hepatitis C Virus Infection with Genotypes 1 and 4 in Children Aged 12 to 17 Years—Results of the POLAC Project
by: Maria Pokorska-Śpiewak, et al.
Published: (2021-09-01)

Effectiveness of Direct-Acting Antivirals in Treatment of Elderly Egyptian Chronic Hepatitis C Patients
by: Shimaa Kamel, et al.
Published: (2021-07-01)

Estimating the cost-effectiveness of daclatasvir + sofosbuvir versus sofosbuvir + ribavirin for patients with genotype 3 hepatitis C virus
by: Phil McEwan, et al.
Published: (2017-07-01)

Prescription and efficacy of daclatasvir and sofosbuvir ± ribavirin for hepatitis C infection, including patient-reported outcomes, in routine practice in three European countries: The CMPASS-EU cohort study
by: Stefan Bourgeois, et al.
Published: (2020-01-01)

Comparative efficacy and safety of Sofosbuvir/Velpatasvir and Danoprevir for the treatment of chronic hepatitis C: the real-world data in China
by: Yunjing Zhou, et al.
Published: (2024-02-01)

Treatment outcomes and costs of a simplified antiretroviral treatment strategy for hepatitis C among Hepatitis C Virus and Human Immuno deficiency Virus co‐infected patients in Ukraine
by: Sergie Antoniak, et al.
Published: (2022-12-01)

A reduced dose of ribavirin does not influence the virologic response during pegylated interferon alpha-2b and ribavirin combination therapy in patients with genotype 1 chronic hepatitis C
by: Byung Chul You, et al.
Published: (2012-09-01)

Peginterferon alfa-2a plus ribavirin for hemophilic patients with chronic hepatitis C virus infection in Taiwan
by: Jung-An Lin, et al.
Published: (2014-10-01)

Sofosbuvir/velpatasvir/voxilaprevir plus ribavirin for chronic hepatitis C patients with direct acting antiviral failures: Implications for viral elimination in Taiwan
by: Chen-Hua Liu, et al.
Published: (2020-12-01)

Efficacy and safety of peginterferon alfa-2a and ribavirin treatment of chronic hepatitis C in the Republic of Serbia
by: Božić Milena, et al.
Published: (2012-01-01)

Treatment of HEV Infection in Patients with a Solid-Organ Transplant and Chronic Hepatitis
by: Nassim Kamar, et al.
Published: (2016-08-01)

Response Tailored Protocol Versus the Fixed 12 Weeks Course of Dual Sofosbuvir/Daclatasvir Treatment in Egyptian Patients With Chronic Hepatitis C Genotype-4 Infection: A Randomized, Open-label, Non-inferiority Trial
by: Mostafa Yakoot, et al.
Published: (2017-07-01)

Nepremičninske evidence in novi koordinatni sistem v luči direktive INSPIRE : Real Estate Databases And The New Coordinate System In Relation To The Inspire Directive
by: Sandi Berk, et al.
Published: (2010-01-01)

Very rapid virologic response and early HCV response kinetics, as quick measures to compare efficacy and guide a personalized response-guided therapy
by: Yakoot M, et al.
Published: (2016-08-01)

Treatment Efficacy of Sofosbuvir and Ribavirin Combination at Two Weeks in Chronic Hepatitis C
by: Aqsa Naseer
Published: (2017-12-01)

Treatment of hepatitis C virus genotype 3 infection with direct-acting antiviral agents
by: L.P. Zanaga, et al.

Therapy with interferon-alpha plus ribavirin for membranoproliferative glomerulonephritis induced by hepatitis C virus
by: Edmundo P.A. Lopes, et al.